Results 21 to 30 of about 5,866 (194)

Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies

Journal of Translational Medicine, 2010
Background Pegylated granulocyte colony-stimulating factor (G-CSF; pegfilgrastim) is a longer-acting form of G-CSF, whose effects on dendritic cell (DC) and regulatory T cell (Treg) mobilization, and on the in vivo and ex vivo release of immune ...
De Cristofaro Raimondo, Danese Silvio, Perillo Alessandro, Corallo Maria, Mariotti Andrea, Procoli Annabella, Bonanno Giuseppina, Scambia Giovanni, Rutella Sergio   +8 more
doaj   +1 more source

Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim

Cancer Medicine, 2020
Our aim was to compare the efficacy and safety of two recently developed biosimilars of pegfilgrastim, a pegylated form of the recombinant human granulocyte‐colony stimulating factor (G‐CSF) analog filgrastim with those of the reference pegfilgrastim. We
Ka‐Won Kang, Byung‐Hyun Lee, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Chul Won Choi, Yong Park, Byung Soo Kim   +9 more
doaj   +1 more source

Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)

BMC Cancer, 2013
Background Myelosuppressive chemotherapy can lead to dose-limiting febrile neutropenia. Prophylactic use of recombinant human G-CSF such as daily filgrastim and once-per-cycle pegfilgrastim may reduce the incidence of febrile neutropenia.
Naeim Arash, Henk Henry J, Becker Laura, Chia Victoria, Badre Sejal, Li Xiaoyan, Deeter Robert   +6 more
doaj   +1 more source

A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim

Case Reports in Oncological Medicine, 2022
Checkpoint inhibitors (CPIs) and pegfilgrastim, a long-acting growth factor agent, are vital components of current cancer treatments. Immune-related adverse events (irAEs) such as colitis and pneumonitis are well-established toxicities associated with ...
Joseph Mort, Shipra Maheshwari, Nayanika Basu, Patrick Dillon, Kevin Brady, Harry Bear, Trish Millard   +6 more
doaj   +1 more source

A Pilot Study to Evaluate the Role of Therapeutic Drug Monitoring of Pegfilgrastim in Lymphoma Patients Receiving Chemotherapy

Proceedings of Singapore Healthcare, 2014
Background: Despite primary prophylaxis of febrile neutropenia (FN) with pegfilgrastim, studies have demonstrated a significant number of breakthrough FN events among Asian lymphoma patients receiving chemotherapy.
Michelle See PharmD, Vivianne Lee Chuen Shih PharmD, BCPS, BCOP, Han Kiat Ho PhD, Tiffany Pooi Ling Tang MBBS, MRCP, Mohamad Farid MBBS, MMed (Internal Medicine), MRCP, Richard Hong Hui Quek MBBS, MRCP, Miriam Tao MBBS, FAMS, FHKAM, FHKCP, MRCP, Soon Thye Lim MBBS, MRCP, Alexandre Chan PharmD, MPH, BCPS, BCOP   +8 more
doaj   +1 more source

Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study

BMC Cancer, 2019
Background Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy. Clinical practice guidelines recommend routine prophylactic coverage with granulocyte colony-stimulating factor (G-CSF)—such as pegfilgrastim—for most ...
Derek Weycker, Robin Doroff, Ahuva Hanau, Charles Bowers, Rajesh Belani, David Chandler, Alexander Lonshteyn, Mark Bensink, Gary H. Lyman   +8 more
doaj   +1 more source

Immunogenicity Assessment of Pegfilgrastim in Patients with Breast Cancer

Разработка и регистрация лекарственных средств, 2020
Introduction. Neutropenia, which is an abnormally low concentration of neutrophils in the blood, is one of the common side effects in patients receiving radio- or chemotherapy.
Yu. V. Medvedev, M. A. Kolganova, O. A. Sas, T. N. Komarov, E. N. Fisher, I. E. Shohin, Yu. I. Ammour   +6 more
doaj   +1 more source

Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors

Frontiers in Oncology, 2022
It has been reported that chemotherapy drugs and granulocyte colony-stimulating factor (G-CSF) administered on the same day can aggravate neutropenia.
Ryunosuke Nakagawa, Hiroaki Iwamoto, Tomoyuki Makino, Suguru Kadomoto, Hiroshi Yaegashi, Masashi Iijima, Shohei Kawaguchi, Takahiro Nohara, Kazuyoshi Shigehara, Kouji Izumi, Yoshifumi Kadono, Atsushi Mizokami   +11 more
doaj   +1 more source

Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil

World Journal of Surgical Oncology, 2019
Background The docetaxel, 5-fluorouracil, and cisplatin (DCF) regimen is an effective form of chemotherapy for advanced esophageal cancer. However, the incidence of adverse events such as febrile neutropenia and hematological toxicity is high.
Yu Ohkura, Masaki Ueno, Harushi Udagawa
doaj   +1 more source

Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)

BMC Cancer, 2021
Background A classification tree was used to analyze background factors for granulocyte colony-stimulating factor (G-CSF) preparation selection for febrile neutropenia (FN) prophylaxis in Japanese patients with non-Hodgkin B-cell lymphoma receiving the ...
Masahiro Yokoyama, Yoshiharu Kusano, Norihito Inoue, Noriko Nishimura, Yuko Mishima, Tomoyuki Nukada, Kiyohiko Hatake, Yasuhito Terui   +7 more
doaj   +1 more source